The largest lipidomics study to date analyzing skin lipids in more than 250 skin samples has been published in “Scientific Reports” (Sadowski T. et al. “Large-scale human skin lipidomics by quantitative, high-throughput shotgun mass spectrometry.” Scientific Reports 2017, doi: 10.1038/srep43761). The study applied a novel Skin Lipidomics Technology Platform developed by Lipotype GmbH, a German Max-Planck-Institute spin-off. Results showed that the skin lipidome varies with respect to sampling depth, site, age and subject. This variation seems to be driven, mainly by secretion of sebaceous lipids and this finding could have an intriguing impact on the design of cosmetic products. Results also reveal a high inter-individual variation of the lipid profile of each person, which could become the basis for the development of personalized cosmetics. Read more
Discover how skin lipidomics can be applied for your research and product development and get the White Paper.
Meet us at in-cosmetics in London (04th -06th of April 2017): Schedule an individual appointment
Lipotype Shotgun Lipidomics coupled with the novel superparamagnetic nanoparticles-based organelle purification uncovers lipid composition of plasma membrane and endosomes in storage disorder diseases.
Lipotype Shotgun Lipidomics applied to mitochondria helps to link the lipid metabolism with the electron transport via action of phosphatase and tensin homologue–induced kinase (PINK1), a protein associated with Parkinson’s disease.
An Innovative Medicines Initiative (IMI) Project for Precision Medicine in Diabetic Kidney Disease
with Lipotype as project partner
BEAt-DKD (“Biomarker Enterprise to Attack Diabetic Kidney Disease”), a unique public private partnership funded by the Innovative Medicines Initiative (IMI), member companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Juvenile Diabetes Research Foundation (JDRF) and the state of Switzerland has announced the launch of a 5-year project (total budget 28.9 Million Euro) with the aim to improve prevention and management of Diabetes Kidney Disease (DKD).
Leading experts from 21 academic institutions, 6 EFPIA pharmaceutical companies, 1 biotech company and JDRF launched BEAt-DKD to provide a holistic systems medicine view of the pathogenesis and heterogeneity of DKD, with the goal to identify targetable mechanisms and pathways underlying initiation and progression of DKD, as well as to identify and validate biomarkers of disease progression and treatment responses, representing first steps towards precision medicine in DKD. Lipotype is project partner in this consortium.
Please download the official press release of the BEAt-DKD consortium here
Zhou et al. show that K-Ras C-terminal membrane anchor encodes an previously unsuspected anionic lipid binding specificity, which is realized by defined conformational structures of the anchor. Subtle changes to anchor sequence or prenylation profoundly alter its lipid specificity and is a key determinant of K-Ras signal output.
Lipotype is proud of its contribution to this exciting study.
In the latest issue of the Journal of the American Heart Association, Lipotype and Lund University published a paper in which high-throughput lipidomic screening was successfully applied to reveal molecular lipid profiles in blood serum specific for Diabetes mellitus and myocardial infarction.
Berlin/Dresden, 4 November 2016: Kai Simons, founding director of the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) and managing director of Lipotype GmbH, receives the Robert Koch Medal in Gold for his lifetime achievements, in particular for his characterization of membrane-forming lipids and the development of the lipid raft concept. The Award Ceremony takes place on Friday, November 4th 2016 at the Berlin-Brandenburg Academy of Sciences and Humanities.
During the award ceremony at the Berlin-Brandenburg Academy of Sciences and Humanities, Kai Simons received the award from Annette Widmann-Mauz, Parliamentary State Secretary, and Dr. Hubertus Erlen, Chairman of the Board of Directors of the Robert Koch Foundation.
Lipotype GmbH, a German Max-Planck spin-off company, launched its novel Lipotype Shotgun Skin Lipidomics Technology and offers lipid analysis services for applications such as cosmetic claim support, topical drug development, efficacy testing for dermatological pharmacology and the cosmetic industry.
High-throughput skin lipidomics with ultra-broad fully quantitative coverage
Until recently, investigating skin lipidomes was not a trivial task. On one hand, the analytical method needs to have coverage broad enough to encompass the variety of skin lipids, and a throughput allowing for statistically relevant studies. On the other hand the method should be compatible with a convenient sampling technique such as tape stripping. These prerequisites are now met in the Lipotype Shotgun Skin Lipidomics Technology platform as explained by Prof. Kai Simons, CEO of Lipotype: “We offer unprecedented throughput of hundreds of samples, absolutely quantified with broad coverage of ceramides, triglycerides and other lipids, and this is all available for samples collected by super-easy tape stripping.” The development of Lipotype Skin Lipidomics was supported by the German Central Innovation Programme for SMEs.
Applications of skin lipidomics
With tools such as Lipotype Skin Lipidomics it is now easy to investigate how the healthy skin lipidome is composed, how it changes in diseases or upon intervention with a drug or a cosmetic product. This lipidomic data can be used for cosmetic claim support, topical drug development and efficacy testing. “We are excited about new possibilities to include skin lipidomics in the product development process of cosmetics companies as well as for biomarker identification for dermatology”, says Dr. Oliver Uecke, Head of Business Development and Finance at Lipotype GmbH.
Meet Dr. Oliver Uecke and our scientist Dr. Christian Klose for a scientific talk held in Ghent on the 20th of October at 2pm and in Leuven on the 21st of October at 9:30am. They will inform you how Lipidomics could strengthen your research.
Lipotype is a spin-off company from the MPI-CBG. You will meet Prof. Kai Simons, CEO of Lipotype and founding director of the MPI-CBG as well as Lipotype team members who were trained at the MPI-CBG. Dr. Christian Klose, Head of R&D will give a flash talk. We’re looking forward to catch up with old colleagues and to grow our network – Join the lipid revolution!
Meet Lipotype’s scientist Dr. Christian Klose at the Campus Carité Mitte of Charité Univeristätsmedizin Berlin who will inform you about our ‘Lipotype Shotgun Lipidomics technology for quantitative high throughput lipid analysis’ in a scientific talk. The talk will be held at 2pm at the Center for Cardiovascular Research.
We will be poster price sponsor of this important lipidomics event in Germany. Dr. Ronny Herzog will announce the winner for the best poster on the last conference day, the 15th of November at 12:30pm.
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.